Given that MMP-2 inhibition can re-open the P2RX7 LP in cancer cells and effectively switch on the LP-associated cell death pathway, it might be possible to develop a new generation of cancer therapeutics promoting this P2RX7 LP formation (Young et al., 2017). The gene discussed is P2RX7; the disease is cancer.